Next 10 |
home / stock / clvly / clvly news
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE ® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company ...
MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California’s most prolific investors and philanthropists at the Malibu home of Lady Gaga and Michael Polansky. The event, hosted by Lady Gaga and M...
2024-02-23 10:16:21 ET More on Clinuvel Pharmaceuticals Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript Historical earnings data for Clinuvel Pharmaceuticals Dividend scorecard for Clinuvel Pharmaceuticals Financial information for C...
2024-02-23 01:12:09 ET Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript February 22, 2024 02:00 AM ET Company Participants Verity Wai-Smith - Monsoon Communications Malcolm Bull - Head of Australian Operations and Investor Relations Darre...
2024-01-31 15:19:39 ET Summary Disc Medicine, Inc. has seen a strong rally in its stock after positive open-label data from its lead heme biosynthesis program, bitopertin. Results from a placebo-controlled trial, expected in early 2024, will validate bitopertin's efficacy and coul...
UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) -- CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level 1: CLVLY) today launched CYACÊLLE, a next generation of polychromatic solar care...
MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summary Positive Results in the Half Year to 31 December 2022 19% increase in revenues from clinical demand for SCENESSE® (afamelanotide 16mg). 94% increase in NPAT; 67% increase in EBIT. Net assets...
MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical study have shown that the drug afamelanotide can reduce critical skin damage caused by ultraviolet (UV) radiation, a leading factor in skin cancer and photoaging. The CUV151 study, conducted by Australi...
MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of skin cancers. The trial results are the first showing the potential of afamelanotide...
MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug afamelanotide – approved by US and European regulators for a rare light intolerance disorder –...
News, Short Squeeze, Breakout and More Instantly...
Clinuvel Pharms Ltd S/Adr Company Name:
CLVLY Stock Symbol:
OTCMKTS Market:
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE ® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company ...
MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California’s most prolific investors and philanthropists at the Malibu home of Lady Gaga and Michael Polansky. The event, hosted by Lady Gaga and M...
UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) -- CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level 1: CLVLY) today launched CYACÊLLE, a next generation of polychromatic solar care...